P-381 Mezigdomide (CC-92480) activates innate and adaptive immune populations in the bone marrow microenvironment of heavily pre-treated multiple myeloma patients

Autor: Chen, Lucia, Amatangelo, Michael, van Oekelen, Oliver, Upadhyaya, Bhaskar, Lagana, Alessandro, Kelly, Geoffrey, Kim-Schulze, Seunghee, Aleman, Adolfo, Chow, Tracy, Kurtova, Antonina, Gandhi, Anita, Gooding, Sarah, Jagannath, Sundar, Thakurta, Anjan, Flynt, Erin, Oppermann, Udo, Parekh, Samir
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 2:S250-S250
Databáze: ScienceDirect
Externí odkaz: